恶性血液病患者血清中可溶性Fas水平的测定

Measurement of soluble Fas in patients with hematological malignancy

用ＥＬＩＳＡ法测定６８例恶性血液病患者血清可溶性４８ｋＤ跨膜糖蛋白（ｓＦａｓ）水平，用免疫组织化学ＳＡＢＣ法检测其中４６例急性白血病患者骨髓单个核细胞膜Ｆａｓ（ｍＦａｓ）阳性表达细胞数。以患者不同病期及其他临床资料分组，比较各组ｓＦａｓ水平，并对５例急性淋巴细胞白血病（ＡＬＬ）患者进行治疗前后的ｓＦａｓ随访。结果显示，ＡＬＬ组和Ｈｏｄｇｋｉｎ’ｓ淋巴瘤组血清ｓＦａｓ高于正常对照组，且与疾病的发展和病期可能相关。提示ｓＦａｓ可作为临床监测和判断预后的有效指标。急性非淋巴细胞白血病患者（ＡＮＬＬ）血清ｓＦａｓ水平与正常对照差异无显著性。

We measured serum levels of soluble Fas(sFas) in 68 patients with hematological malignancy by using sandwich ELISA and detected bone marrow mononuclear cell membrane Fas(mFas) positive cells in 46 patients with acute leukemias by immunohistochemical technic. It was found that sFas levels were significantly higher in acute lymphoblastic leukemia(ALL) patients(median 10.48±5.89ng·ml -1 ) and non Hodgkin's lymphoma(NHL) patients(median 18.26±16.47ng·ml -1 ) than those in healthy donors(median 0.92±0.88ng·ml -1 )( P <0.05). Elevated sFas levels were correlated with the disease stage and progress, but not with other clinical parameters. According to the follow up of five ALL patients, their serum sFas levels decreased after complete remissions. We conclude that sFas has prognostic value and is an effective clinical parameter with ALL or NHL patients. In addition, sFas levels in the sera of acute non lymphoblastic leukemia patients were also found to be unchanged compared with those in the normal control.